The procedure of informed consent for tPA treatment in acute ischemic stroke faces various challenges: 1) tPA treatment’s efficacy increases with earlier administration [11], 2) the decision-making process takes place in an acute setting, 3) in most cases, an alternative therapy is lacking [12], and 4) obtaining consent can be difficult in stroke patients with neurological deficits (e.g. aphasia) [13]. The gene discussed is PLAT; the disease is Stroke.